EMILIO
BOUZA SANTIAGO
Investigador hasta 2020
Medical University of Vienna
Viena, AustriaPublicaciones en colaboración con investigadores/as de Medical University of Vienna (5)
2019
-
Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (European Journal of Clinical Microbiology & Infectious Diseases, (2018), 37, 11, (2097-2106), 10.1007/s10096-018-3344-1)
European Journal of Clinical Microbiology and Infectious Diseases
2018
-
Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 37, Núm. 11, pp. 2097-2106
2016
-
ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 9, pp. 2405-2413
-
Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: An individual participant data meta-analysis
Influenza and other Respiratory Viruses, Vol. 10, Núm. 3, pp. 192-204
2014
-
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data
The Lancet Respiratory Medicine, Vol. 2, Núm. 5, pp. 395-404